Journal Information

Statistics

Follow this link to access the full text of the article

Letter - Research
Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients
Analú Viviana, Vania Oliveira de Carvalhob, Ana Elisa Kiszewskia,c,d,
Corresponding author
kiszewski@gmail.com

Corresponding author.
a Service of Dermatology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
b Department of Pediatrics, Universidade Federal do Paraná, Curitiba, PR, Brazil
c Department of Internal Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
d Pediatric Dermatology Unit, Hospital da Criança Santo Antônio, Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil
Read
4697
Times
was read the article
1354
Total PDF
3343
Total HTML
Share statistics
Article information
ISSN: 03650596
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 September 156 64 220
2024 August 294 148 442
2024 July 258 111 369
2024 June 182 84 266
2024 May 186 62 248
2024 April 212 88 300
2024 March 159 85 244
2024 February 171 106 277
2024 January 149 64 213
2023 December 705 81 786
2023 November 285 145 430
2023 October 318 128 446
2023 September 88 93 181
2023 August 97 43 140
2023 July 83 52 135
Show all

Follow this link to access the full text of the article

Idiomas
Anais Brasileiros de Dermatologia
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.